Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1803 results
July 2019
-
Media ReleaseNovartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's preventionAfter review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11…
-
Flexibility at Novartis: Janneke van der Kamp
Van der Kamp explains how leading by example has encouraged others to adopt flexible working models.
-
Featured NewsGlobal Health & Corporate Responsibility
Novartis transforms its Global Health & Corporate Responsibility organization.
-
Media ReleaseSandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicineSandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women…
-
Media ReleaseNovartis highlights cognition data in secondary progressive multiple sclerosis (SPMS)Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary…
-
Key ReleaseNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolioBasel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both…
-
Media ReleaseNovartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapiesData from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures …
-
Media ReleaseNovartis data underpin long-term efficacy of Aimovig® where other treatments have failedData from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
June 2019
-
Media ReleaseNovartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasisNew data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1]…
-
Flexibility at Novartis: Christine Sturchler and Aileen Wrynn
Sturchler and Wrynn explain why their job-sharing experience was one of the most successful and energizing periods of their careers.
-
Media ReleaseNovartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosisConatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in…
-
Featured NewsWorld Sickle Cell Day 2019
For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.
Pagination
- ‹ Previous page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- …
- 151
- › Next page